Core Viewpoint - Yiming Anke-B (01541.HK) has successfully completed a placement agreement, raising approximately HKD 345.1 million for various research and operational purposes [1] Group 1: Placement Details - The placement involved the successful allocation of 24.2 million shares at a price of HKD 14.50 per share, representing about 5.94% of the company's issued share capital prior to the placement [1] - The shares allocated account for approximately 6.11% of the total issued H-shares before the placement and about 5.61% and 5.76% of the issued share capital and H-shares, respectively, after the placement [1] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors [1] - About 20% will be used for the development of IMM01 (Tideglusib) [1] - Approximately 10% will be directed towards the research of IMM0306 [1] - The remaining 30% will be utilized to supplement the company's working capital and for general corporate purposes [1]
宜明昂科-B(01541.HK)完成配售2420万股 净筹3.451亿港元